Trials Of FGF1 Protein
The researchers have found a direct to the brain treatment for type 2 diabetes (T2D) by injecting a single dose of Fibroblast Growth Factor 1 (FGF1) hormone into the brain via the intranasal route. The mice models have experienced a relief (for 17 weeks) from type 2 diabetes (T2D) with no change in the diet or weight. A 17-week lifespan of mice is equivalent to a 12-year lifespan of a human.
The researchers believe that the brain can control blood sugar (glucose) levels after injecting the FGF1. This type of diabetes remission was seen only in bariatric surgery. There is a wide range of medications available for the treatment of type 2 diabetes. But all the treatments will require substantial weight loss for the success of the treatment.
The authors say that a relief from type 2 diabetes is not dependent on weight loss, diet changes or exercises. Authors say that the intranasal delivery of FGF1 into the brain is possible.
The study was led by Michael W. Schwartz (endocrinologist), Jarrad M. Scarlett (gastroenterologist) and Jennifer M. Rojas (molecular physiologist). The study was published in Nature Medicine.
Risk In Postmenopausal Women
A study has found an increased risk of atherosclerotic cardiovascular disease in postmenopausal women diagnosed with diabetes even if they are taking statins therapy. In general, statins can reduce the risk of atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular events are.
But, statin therapy is increasing the risk of diabetes. The researchers have hypothesized that the risk of atherosclerotic cardiovascular disease will be milder. The study shows it is important for postmenopausal women to monitor, diagnose and prevent diabetes, even if they are taking statins.
The lead author of the study was Prof Yunsheng Ma and co-author of the study was JoAnn E Manson, UMass Medical School. The study was published in the European Journal of Epidemiology.
The Risk Associated With Poor Lifestyle
Gestational diabetes (GD) can lead to type 2 diabetes (T2D) due to genes. The gene expression can change due to a change to the histones in our cells. Poor lifestyle habits will lead to a change in histones. A two-year long study has measured the levels of histones in four groups of women during the pregnancy and postpartum. They are.
The researchers have found that the histones are different between women who have type 2 diabetes (T2D) after gestational diabetes and women without type 2 diabetes (T2D) after gestational diabetes. Prof Leigh says that this study can help medical professionals in predicting the risk of type 2 diabetes (T2D) in patients with gestational diabetes.
The author of the study was Prof Leigh Ackland, Deakin University. The study was published in the Journal of Clinical Endocrinology and Metabolism.
Health Benefits Of Trans-Resveratrol (tRES) And Hesperetin (HESP)
A study conducted by Paul Thornalley, a Professor at Warwick, has suggested that the red grapes and oranges (taken together) can provide a new treatment for obesity, diabetes and cardiovascular disease (CVD). The new treatment was found to be more effective than metformin. Methylglyoxal (MG) is the key driver for the harmful effects of sugar in the body.
The high levels of MG and a high-calorie diet is the cause of the insulin resistance. Methylglyoxal (MG) can damage the blood vessels and also increase the cholesterol levels (a risk factor for CVD).
The researchers have found trans-resveratrol (tRES) in red grapes and Hesperetin (HESP) in oranges. A combination of red grapes and oranges can increase the Glo1. Glo1 is an enzyme that can neutralize the compound called methylglyoxal (MG).
The study has received funding from the UK's innovation agency, Innovate UK. The study was published in the journal Diabetes.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.